在流行地区关于基孔肯雅热活疫苗的首批免疫原性和安全性数据。 - Suppr

Suppr

超能文献

First immunogenicity and safety data on live chikungunya vaccine in an endemic area.

作者信息

Freedman David O, Wilder-Smith Annika Beate, Wilder-Smith Annelies

机构信息

University of Alabama at Birmingham, Birmingham, AL, USA.

John Radcliffe Hospital Oxford, Oxford, UK.

出版信息

Lancet Infect Dis. 2025 Jan;25(1):11-13. doi: 10.1016/S1473-3099(24)00510-3. Epub 2024 Sep 5.

DOI:10.1016/S1473-3099(24)00510-3

PMID:39243791

Abstract

摘要

相似文献

First immunogenicity and safety data on live chikungunya vaccine in an endemic area.在流行地区关于基孔肯雅热活疫苗的首批免疫原性和安全性数据。

Lancet Infect Dis. 2025 Jan;25(1):11-13. doi: 10.1016/S1473-3099(24)00510-3. Epub 2024 Sep 5.

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.减毒活基孔肯雅病毒疫苗在巴西流行地区的安全性和免疫原性：青少年双盲、随机、安慰剂对照3期试验的中期结果

Lancet Infect Dis. 2025 Jan;25(1):114-125. doi: 10.1016/S1473-3099(24)00458-4. Epub 2024 Sep 5.

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.一项随机、双盲3期研究，旨在证明减毒活基孔肯雅病毒候选疫苗VLA1553在健康成年人中的批次间一致性，并确认其免疫原性和安全性† 。

J Travel Med. 2024 Mar 1;31(2). doi: 10.1093/jtm/taad156.

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.基于重组麻疹病毒的基孔肯雅疫苗的免疫原性、安全性和耐受性：一项随机、双盲、安慰剂对照、活性对照、首次人体试验。

Lancet Infect Dis. 2015 May;15(5):519-27. doi: 10.1016/S1473-3099(15)70043-5. Epub 2015 Mar 2.

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.一种单次接种的减毒活寨卡病毒疫苗的安全性和免疫原性：一项双盲、多中心、随机、安慰剂对照、3 期临床试验。

Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12.

From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.从实验室到临床：减毒活疫苗 VLA1553/IXCHIQ 的研发。

J Travel Med. 2024 Oct 19;31(7). doi: 10.1093/jtm/taae123.

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.基于麻疹病毒的基孔肯雅病毒疫苗 MV-CHIK 的免疫原性、安全性和耐受性：一项双盲、随机、安慰剂对照和阳性对照的 2 期临床试验。

Lancet. 2019 Dec 22;392(10165):2718-2727. doi: 10.1016/S0140-6736(18)32488-7. Epub 2018 Nov 5.

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.单次减毒活寨卡病毒疫苗在健康成年人中的应用：一项 1 期、随机对照试验。

Lancet Infect Dis. 2020 Oct;20(10):1193-1203. doi: 10.1016/S1473-3099(20)30238-3. Epub 2020 Jun 1.

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis.基孔肯雅热疫苗的免疫原性和安全性：一项系统评价与荟萃分析。

Vaccines (Basel). 2024 Aug 27;12(9):969. doi: 10.3390/vaccines12090969.

Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.基孔肯雅病毒病毒样颗粒疫苗在基孔肯雅血清阳性个体中具有良好的耐受性和免疫原性。

Vaccine. 2023 Oct 6;41(42):6146-6149. doi: 10.1016/j.vaccine.2023.08.086. Epub 2023 Sep 9.

引用本文的文献

Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.2023 - 2024年获批的全球首创药物：突破与见解。

Innovation (Camb). 2025 Jan 14;6(4):100801. doi: 10.1016/j.xinn.2025.100801. eCollection 2025 Apr 7.

Extracellular vesicles in arbovirus infections: from basic biology to potential clinical applications.虫媒病毒感染中的细胞外囊泡：从基础生物学到潜在临床应用

Front Cell Infect Microbiol. 2025 Apr 28;15:1558520. doi: 10.3389/fcimb.2025.1558520. eCollection 2025.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验